Skip to main content
. 2012 Nov 8;24(4):909–916. doi: 10.1093/annonc/mds530

Table 3.

Multivariable models for recurrence-free survival in all patients and in patients with HR-positive tumors

Variables Recurrence-free survival
Hazard ratio 95% confidence interval P-value
All patients
Breast cancer subtype
 HR positive 1.0
 HER2 positive 2.58 0.97–6.83 0.0572
 Triple receptor negative 2.13 0.83–5.48 0.117
Clinical stage at diagnosis
 I and II 1.0
 III 1.02 0.515–2.029 0.95
Nuclear grade
 1 and 2 1.0
 3 1.64 0.56–4.79 0.362
Residual cancer burden (continuous) 1.01 0.99–1.02 0.346
Risk score all patients (RS-All) 2.09 1.36–3.21 0.0008
Patients with HR-positive disease
Clinical stage at diagnosis
 I and II 1.0
 III 0.33 0.08–1.43 0.1388
Nuclear grade
 1 and 2 1.0
 3 2.2 0.59–8.43 0.2405
Residual cancer burden (continuous) 1.02 0.99–1.05 0.2211
Risk score HR positive (RS-HR) 2.87 1.31–6.26 0.0083